Evidence map›Paper›PMID 32509470›Full record

ArticlePeerJ2020

Evaluation of the effective dose of amygdalin for the improvement of antioxidant gene expression and suppression of oxidative damage in mice.

Sarah Albogami, Aziza Hassan, Nibal Ahmed, Alaa Alnefaie, Afnan Alattas, Lama Alquthami, Afaf Alharbi

Open access · goldAbstract read
In one paragraph

Article in PeerJ, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
5.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Onco-immunity and therapeutic application of amygdalin: A review.Journal of oral biology and craniofacial research
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 2 countries.

Sarah AlbogamiDepartment of Biotechnology, Faculty of Science, Taif University, Taif, Makkah, Kingdom of Saudi Arabia.
Aziza HassanDepartment of Biotechnology, Faculty of Science, Taif University, Taif, Makkah, Kingdom of Saudi Arabia.
Nibal AhmedDepartment of Biology, Faculty of Science, Taif University, Taif, Makkah, Kingdom of Saudi Arabia.
Alaa AlnefaieDepartment of Biotechnology, Faculty of Science, Taif University, Taif, Makkah, Kingdom of Saudi Arabia.
Afnan AlattasDepartment of Biotechnology, Faculty of Science, Taif University, Taif, Makkah, Kingdom of Saudi Arabia.ORCID 0000-0002-1495-4812
Lama AlquthamiDepartment of Biotechnology, Faculty of Science, Taif University, Taif, Makkah, Kingdom of Saudi Arabia.
Afaf AlharbiDepartment of Biotechnology, Faculty of Science, Taif University, Taif, Makkah, Kingdom of Saudi Arabia.
Taif University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLittle is known regarding the toxic and therapeutic doses of amygdalin. Treatment regimens and schedules can vary between humans and animal models, and there have been reports of cyanide toxicity due to amygdalin use.

objectiveThe aim of this study was to evaluate the effect of different doses of amygdalin on antioxidant gene expression and suppression of oxidative damage in mice.

methodsForty adult male mice were divided randomly into four groups (

resultsThe mice treated with medium-dose amygdalin (100 mg/kg) showed upregulated mRNA expression of glutathione peroxidase (

conclusionLow-and medium-dose amygdalin did not induce toxicity in the hepatic and testicular tissues of male mice, unlike high-dose amygdalin, which had a negative effect on oxidative balance in mice. Therefore, amygdalin at a moderate dose may improve oxidative balance in mice.

Indexed as

AmygdalinAntioxidantGSH-PxHepatic and testicular tissuesHistopathologyLPOSODs mRNA expression

Identifiers

PMID32509470
PMCPMC7246030
OpenAlexW3027982218

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.